ValuentumAd

Official PayPal Seal
Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Jul 31, 2017
A Review of Johnson and Johnson’s Pharmaceutical Division
Image Source: J&J. Let’s take a deep dive into Johnson and Johnson’s pharmaceutical division Janssen Pharmaceuticals. Janssen traditionally serves as an area of clinical innovation adding an element of growth to the more stable product categories such as consumer health. However, there may be a few cracks in the Janssen revenue stream that could make growth at J&J harder to come by over the next few years.
Jul 27, 2017
Hasbro Hit by Gross Margin, Timing Issues
Shares of Dividend Growth Newsletter portfolio holding Hasbro dropped after the company reported its second quarter earnings. We're watching shares closely.
Jul 26, 2017
General Motors May Offer an Incredible Opportunity
We continue to believe GM’s valuation and dividend profile may be too good to pass up. At the very least, it should receive a multiple on current-year earnings like that of the airlines, another cyclical boom-or-bust industry that has traditionally been associated with bankruptcy.
Jul 25, 2017
Earnings Roundup: McDonald’s, 3M, IBM
Let’s recap a few big earnings announcements.
Jul 21, 2017
Stocks in the News: Visa, Microsoft, General Electric
Image source: Visa. Let’s have a look at the quarterly reports from a few stocks in the news July 21.
Jul 18, 2017
Stocks in the News: Harley-Davidson, Johnson & Johnson, Netflix
Earnings season is picking up. Let’s evaluate a few quarterly reports from some bellwethers.
Jul 17, 2017
ETF Analysis: Consumer Staples
The consumer staples sector boasts some of the strongest business models, but investors should not ignore the lofty valuations of underlying ETF constituents.
Jul 15, 2017
Valuentum's July Edition of Its Best Ideas Newsletter
The link to download the July edition of the Best Ideas Newsletter can be found in this article.
Jul 14, 2017
Systemic Risk in These Frothy Times
Image shown: Nelson's Syllogism of the Stock Market. Let’s talk about index investing, market valuations, and mention how a few ideas in the portfolio of the Best Ideas Newsletter are doing.
Jul 12, 2017
Analyzing the S&P SPDR Biotech ETF
Source: S&P SPDR Biotech ETF (XBI). ETFs are rapidly becoming the preferred investment vehicle to gain broad exposure to a particular sector. The biotech industry is no different with two distinct ETFs dominating the niche. The article discusses the unique characteristics of the SPDR Biotech ETF to determine the merits of the idea.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.